Pyroglutamic acidosis in association with therapeutic paracetamol use

Robert W. Hunter*, Cate Lawson, Evangelia Galitsiou, Fiona Gifford, John J. Neary

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Long-term use of paracetamol (at therapeutic doses) can cause the accumulation of endogenous organic pyroglutamate, resulting in metabolic acidosis with an elevated anion gap. This occurs in the presence of malnutrition, infection, antibiotic use, renal failure and pregnancy. Given the prevalence of these risk factors, this condition is thought to be relatively common in a hospitalised population but is probably signifi cantly underdiagnosed. Prompt recognition is essential because the condition is entirely reversible if the causative agents are withdrawn. Here we describe fi ve cases of pyroglutamic acidosis that we have encountered in a tertiary referral hospital. Together they illustrate the common clinical risk factors and the excellent prognosis, once a diagnosis is made. We describe how a rudimentary acid-base analysis (calculation of the anion gap) usually leads to the diagnosis but how a more nuanced approach may be required in the presence of mixed acid-base disorders.

Original languageEnglish
Pages (from-to)524-529
Number of pages6
JournalClinical Medicine, Journal of the Royal College of Physicians of London
Volume16
Issue number6
DOIs
Publication statusPublished - 1 Dec 2016

Keywords / Materials (for Non-textual outputs)

  • 5-oxoproline
  • Acidosis
  • Anion gap
  • Paracetamol
  • Pyroglutamate

Fingerprint

Dive into the research topics of 'Pyroglutamic acidosis in association with therapeutic paracetamol use'. Together they form a unique fingerprint.

Cite this